skip to main content
UK Health Security Agency

MFM-223

MFM-223

Catalogue No.

98050130

Cell Line Name

MFM-223

Cell Line Description

The mammary carcinoma cell line MFM-223 was obtained from the pleural effusion of a postmenopausal breast cancer patient. The patient had not received any prior treatment and the tumour was classified as a widespread ductal mammary carcinoma with the histological grade of III. The cell line is characterised by high androgen, (approximately 100,000 binding sites per cell) and low oestrogen and progesterone receptor levels. Proliferation of cells was inhibited by addition of the androgen dihydrotestosterone at concentrations above 0.01 nM. MFM-223 have a characteristic pattern of isoenzyme polymorphism and of karyotype alterations revealing marker chromosomes and homogenously staining regions. Most cells have been near diploid with 10% displaying near tetraploidy. The cells have been tested to be free of Hepatitis B and C viruses and HIV. MFM-223 is tumourigenic in nude mice.

Characteristics

Receptors

Androgen receptor

Tissue of Origin

Mammary gland

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 10
D5S818: 11,12
D7S820: 8,10
D13S317: 8,12
D16S539: 11
TH01: 6,9.3
TPOX: 8
vWA: 17

Karyotype

Not specified

Applications

Androgen receptor studies, study of mammary carcinoma

Disease

Carcinoma

Culture Conditions

Cell Type

Epithelial-like

Subculture Routine

Split sub-confluent cultures (70-80%) 1:3 i.e. seeding at 2-4x10,000 cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C.This is a relatively slow growing cell line and can take up to 7 days to reach 70% confluence following seeding. Cultures require regular media changes (every 2-3 days) between splits.

Culture Medium

MEM + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).

Growth Mode

Adherent

Additional Info

Depositor

Dr R Hackenberg, Department of Obstetrics and Gynaecology, Am Gesundbrunnen, Heilbronn, Germany

Country of Origin

Germany

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Cancer Res 1991;51;5722, J Steroid Biochem Mol Biol 1992;43;599, Breast Cancer Res Treat 1993;25:217, J Steroid Biochem Mol Biol 1993; 46:597, Eur J Cancer 1996; 32:696

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: MFM-223 (ECACC 98050130).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.